Creatine for Women: Why the Research Finally Caught Up
If you have read anything about creatine and women in the past two years, you have encountered one specific statistic: women have 70 to 80 percent lower endogenous creatine stores than men. It appears in nearly every article on the subject, usually in the first few paragraphs, usually as the justification for why women should supplement.
The statistic is real. It is not marketing. It comes from a peer-reviewed review paper, and the sentence reads almost exactly as it gets quoted.
What almost nobody quotes is the sentence that appears two paragraphs later in the same paper, which changes how that first number should be understood. This post covers both, along with what the research on creatine in women actually establishes, where it is genuinely strong, and where it remains thin enough that honest writing has to say so.
The source everyone cites
The 70 to 80 percent figure traces to Smith-Ryan, Cabre, Eckerson, and Candow, "Creatine Supplementation in Women's Health: A Lifespan Perspective," published in Nutrients in 2021, volume 13, issue 3, article 877. It is an open-access paper, and anyone can read it in full.
The relevant passage states that creatine characteristics vary between males and females, with females exhibiting 70 to 80 percent lower endogenous creatine stores compared to males. The same review notes that females have also been reported to consume significantly lower amounts of dietary creatine than males, and concludes from these two observations that females may benefit from supplementation as a means of increasing endogenous stores.
That is an accurate summary of what the paper says, and it is a reasonable starting point for a conversation about creatine and women. The problem is where most articles stop.
The sentence that gets left out
Within the same section of the same review, the authors also note that females have higher reported resting intramuscular creatine concentrations, by roughly 10 percent.
Read those two findings together and a more precise picture emerges. Total endogenous creatine stores are substantially lower in women. Creatine concentration per unit of muscle is reportedly slightly higher.
Both can be true at once, and the reason is straightforward once you know where creatine lives in the body. Roughly 95 percent of the body's creatine sits in skeletal muscle. Total stores are therefore driven overwhelmingly by how much skeletal muscle a person has. Men, on average, carry more muscle mass. They therefore hold more total creatine. That is a statement about body composition, not about how depleted the tissue itself is.
This matters because of how the 70 to 80 percent figure typically gets deployed. The popular argument runs: women are severely depleted, therefore they have enormous headroom, therefore they will respond more dramatically to supplementation than men would. That argument rests entirely on the first finding and is weakened considerably by the second. If concentration within the tissue is comparable or slightly higher, the "massive untapped headroom" framing is doing more work than the data supports.
None of this means creatine is not worth taking. It means the most-repeated reason for taking it is not quite the reason it is usually presented as, and the actual case is different.
So what is the honest case?
Several genuine, separately supportable reasons emerge from the literature.
Dietary intake is genuinely lower. The same 2021 review notes that women consume significantly less dietary creatine than men. Creatine comes almost exclusively from animal protein, primarily meat and fish, and the body can also synthesize it endogenously from arginine, glycine, and methionine, though that synthesis depends on adequate protein intake. Lower dietary intake is a real gap, and it is a more defensible reason to supplement than a contested claim about depletion.
The research base was built on men. This is the most substantive point, and it is the actual reason this topic has become a research priority. For decades, creatine studies were conducted predominantly on male participants. Early work in women frequently overlooked menstrual cycle variability entirely, which means findings from those studies carry uncertainty that was never measured. The correction of that imbalance is what "the research finally caught up" actually refers to.
Hormonal fluctuations plausibly affect creatine metabolism. A 2025 narrative review by Smith-Ryan, DelBiondo, Brown, Kleiner, Tran, and Ellery, published in the Journal of the International Society of Sports Nutrition, examined this directly across the female lifespan. The review describes how hormonal changes through the menstrual cycle, pregnancy, and menopause can influence creatine synthesis, transport, and creatine kinase expression, and notes that these factors may in turn affect how supplementation works. This is a mechanistically coherent basis for expecting sex-specific differences, and it is the foundation of the current research direction.
What the evidence actually supports
Sorting the findings by strength is more useful than listing them all as equivalent.
Strength and exercise performance in pre-menopausal women. This is the most solid ground. The 2021 review concluded that creatine supplementation among pre-menopausal females appears effective for improving strength and exercise performance. The 2025 review similarly reported positive effects on muscle strength, exercise performance, and body composition, particularly when combined with resistance training.
That last qualifier matters and recurs throughout this literature. Creatine's benefits show up most consistently alongside resistance training, not as a standalone intervention. It supports a training stimulus rather than substituting for one.
Post-menopausal muscle size and function. The 2021 review found that post-menopausal females may experience benefits in skeletal muscle size and function when consuming high-dose creatine, specifically 0.3 grams per kilogram of body weight per day, for at least seven consecutive days. For a 70-kilogram woman that works out to roughly 21 grams daily, which is a loading-phase dose rather than a standard maintenance dose, and worth noting precisely because it differs from the routine 3 to 5 grams most people take.
One example cited in that review, work by Neves and colleagues, used a loading phase of 20 grams daily for seven days followed by a maintenance phase of 5 grams daily for 79 days, alongside 12 weeks of supervised lower-limb resistance training.
Bone health: genuinely less clear. The 2021 review's abstract describes favorable effects on bone when creatine is combined with resistance training in post-menopausal women. Elsewhere in the same paper, discussing specific findings, the text states that creatine supplementation alone or in combination with resistance training appears to provide no benefits in bone physiology in post-menopausal females.
We are flagging that discrepancy rather than picking whichever version is more convenient. What can be said confidently is that bone evidence in this population is less consistent than muscle evidence, and anyone citing creatine as an established bone intervention for post-menopausal women is ahead of what this particular review actually establishes.
Perimenopause specifically: the data is limited, and the reviews say so. This is worth stating plainly because perimenopause is where a great deal of current creatine marketing is aimed. The 2025 review's own conclusion notes that while emerging evidence suggests benefits during pregnancy and post-menopause, data on perimenopausal women remains limited, and identifies perimenopause explicitly as a target for future research.
The mechanistic reasoning for why perimenopause might matter is coherent. The direct evidence in that specific population is not yet there. Both things are true, and content that presents perimenopausal creatine benefits as established is overstating the current literature.
Mood and cognition: promising, early, and worth calibrating
Both reviews discuss potential effects on mood and cognitive function, with the 2025 review noting creatine may improve mood and cognitive function and potentially alleviate symptoms of depression. Earlier work highlighted this application particularly in women.
This is genuinely interesting research, and there is a plausible mechanism behind it, since the brain is a substantial consumer of energy and creatine participates in cellular energy regeneration in neural tissue as it does in muscle.
It also requires the same calibration we have applied elsewhere. In November 2024, the European Food Safety Authority's expert panel evaluated a health claim application linking creatine supplementation to improved cognitive function, reviewed 21 human intervention studies, and concluded that a cause-and-effect relationship had not been established. Notably, Darren Candow, a co-author on the 2021 women's health review and one of the field's more prolific researchers, publicly agreed that decision was justified given the current body of evidence.
So: real mechanism, genuine research interest, encouraging early signals, and a formal regulatory determination that causation is not established. Anyone presenting creatine as a proven cognitive or mood intervention for women is describing a hypothesis as a conclusion. That does not make it uninteresting. It makes it unfinished.
The bloating and water weight question
This is the objection that keeps more women from trying creatine than any other, and it is one place where the research is genuinely reassuring rather than equivocal.
A randomized controlled trial by Moore, Gordon, Cabre, Hackney, and Smith-Ryan, published in Nutrients in 2023, volume 15, issue 2, article 429, examined changes in fluid distribution across menstrual phases with creatine supplementation. The finding, contrary to the common assumption, was that there was no demonstrated significant increase in body mass in women after creatine monohydrate supplementation in any phase of the menstrual cycle.
That is a direct test of the specific fear, in the specific population, across the specific variable people worry about, and it did not find the effect. It is one study rather than a body of replicated work, and worth holding with appropriate weight for that reason, but it is a considerably better answer than the anecdote-versus-anecdote arguments this question usually generates.
Pregnancy: interesting research, not a recommendation
The 2021 Muccini paper, "Creatine Metabolism in Female Reproduction, Pregnancy and Newborn Health," published in Nutrients, was the first to propose creatine as an essential dietary metabolite of pregnancy, describing its role in placental health and fetal growth and metabolism.
This is legitimate, serious research. It is also explicitly not a basis for supplementing during pregnancy. The 2021 lifespan review states directly that there are no human studies to date evaluating the effect of creatine monohydrate supplementation during pregnancy. Mechanistic interest and demonstrated safety in a specific population are different things, and the second has not been established here.
Anyone who is pregnant, trying to become pregnant, or breastfeeding should treat this as a conversation for their obstetric provider rather than something to act on from a supplement article, including this one.
Practical guidance, based on what the research used
For general use in women outside the specific post-menopausal high-dose protocols described above, the standard 3 to 5 grams daily of creatine monohydrate is what the broader literature supports, and no loading phase is required. Loading reaches saturation faster, over roughly a week rather than three to four weeks, but arrives at the same endpoint.
Timing is not a meaningful variable. Creatine works by building and maintaining saturated stores over time rather than through an acute effect, which means consistency matters considerably more than which hour of the day you take it.
Creatine monohydrate is the form with the research behind it. The newer forms marketed as upgrades, including HCl and various proprietary versions, have not demonstrated superiority over monohydrate in head-to-head research, and monohydrate remains both the most studied and the least expensive option.
And because supplements are not reviewed for contents before they reach a shelf, third-party verification of what is actually in the container is worth confirming regardless of which brand you choose. Recent market analysis found that third-party testing and clinical positioning are now outperforming raw review volume as purchase drivers in this category, which suggests buyers have started asking that question themselves.
The honest summary
The 70 to 80 percent figure is real, sourced, and accurately quoted. It is also routinely used to support a conclusion the underlying data does not quite reach, because the same review reports that intramuscular creatine concentration is slightly higher in women, and total stores are largely a function of muscle mass rather than tissue-level depletion.
The genuine case for creatine in women rests on different ground: lower dietary intake, a research base historically built on men that is only now being corrected, and hormonal influences on creatine metabolism that are mechanistically coherent and actively being studied.
The evidence is strongest for strength and exercise performance alongside resistance training, and for muscle size and function in post-menopausal women at higher doses. It is less consistent for bone. It is explicitly limited in perimenopause, according to the reviews themselves. It is early and formally unestablished for cognition and mood. And it does not support the water-weight concern that keeps many women from trying it in the first place.
That is a more qualified picture than the one currently circulating, and it is the one the published research actually supports. The research did finally catch up. What it found is more specific, and more interesting, than the headline statistic suggests.
